Alturos Therapeutics

Alturos Therapeutics is a private Dutch-Belgian biotech focused on developing neuroprotective therapies for Alzheimer's disease and other neurodegenerative disorders. The company's approach is centered on orally bioavailable small molecules designed to address early toxic triggers in neurodegeneration, particularly protein oligomers linked to synaptic loss and neuronal death. Its lead program, ALT0135, is described as a potentially first-in-class small molecule for Alzheimer's disease and, as of June 18, 2026, has advanced into IND-enabling studies. Alturos states that its work is built on a preclinical drug discovery program acquired through an asset deal with Lakefront Biotherapeutics and is supported by in vitro and in vivo efficacy data. The company appears to be raising a Series A financing to support further development toward clinical proof-of-concept.